HIV and pregnancy

AHF Commends the Resumption of HIV Treatment in Kenya – But More Is Needed

Retrieved on: 
Monday, July 26, 2021
Research, General Health, Pharmaceutical, White House, Federal Government, Infectious diseases, Public policy, Other Policy Issues, Science, Biotechnology, AIDS, Health, Public policy, Government, Medical specialties, HIV/AIDS, Health, Clinical medicine, Pandemics, Hepatotoxins, Sexually transmitted diseases and infections, Viral load, HIV, Treatment as prevention, HIV and pregnancy

As a result, distribution of lifesaving HIV/AIDS prevention and treatment medications has resumed as of July 14, according to the US Embassy.

Key Points: 
  • As a result, distribution of lifesaving HIV/AIDS prevention and treatment medications has resumed as of July 14, according to the US Embassy.
  • The damage done to peoples lives and wellbeingparticularly childrens livesis irreversible and must never be repeated.
  • Ensure that HIV management is implemented holistically by taking into consideration prevention and diagnosis, care and treatment, and related essential commodities, including medications.
  • This is urgently needed to address current shortages of paediatric HIV treatment, viral load testing reagents, and HIV test kits.

Jazz to Present New Data at ASCO and EHA 2021 Meetings Showcasing Clinical Advances Across Hematology and Oncology Portfolio

Retrieved on: 
Thursday, May 20, 2021
Health sciences, Health, Medicine, Leukopenia, Breastfeeding, Complete blood count, Prescription drug, HIV and pregnancy, Neonatal sepsis

Your doctor will monitor your blood counts during treatment with VYXEOS.

Key Points: 
  • Your doctor will monitor your blood counts during treatment with VYXEOS.
  • You are encouraged to report negative side effects of prescription drugs to the FDA.
  • Do not breastfeed during treatment with ZEPZELCA and for 2 weeks after your final dose of ZEPZELCA.
  • Some people with low white blood cell counts may get fever, or an infection throughout the body (sepsis), that can cause death.

Jazz to Present New Data at ASCO and EHA 2021 Meetings Showcasing Clinical Advances Across Hematology and Oncology Portfolio

Retrieved on: 
Thursday, May 20, 2021
Health sciences, Health, Medicine, Leukopenia, Breastfeeding, Complete blood count, Prescription drug, HIV and pregnancy, Neonatal sepsis

Your doctor will monitor your blood counts during treatment with VYXEOS.

Key Points: 
  • Your doctor will monitor your blood counts during treatment with VYXEOS.
  • You are encouraged to report negative side effects of prescription drugs to the FDA.
  • Do not breastfeed during treatment with ZEPZELCA and for 2 weeks after your final dose of ZEPZELCA.
  • Some people with low white blood cell counts may get fever, or an infection throughout the body (sepsis), that can cause death.

Global HIV Treatment Markets, Epidemiology and Patient Flow Report 2020-2035 - Focus on US, Germany, France, Italy, Spain, UK, Japan, G7 Countries - ResearchAndMarkets.com

Retrieved on: 
Friday, May 14, 2021
Health, Infectious diseases, HIV/AIDS, Misconceptions about HIV/AIDS, HIV and pregnancy

b'The "Global HIV Treatment Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal HIV Treatment Epidemiology and Patient Flow Analysis - 2021, provides HIV Treatment epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global HIV Treatment Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal HIV Treatment Epidemiology and Patient Flow Analysis - 2021, provides HIV Treatment epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize HIV Treatment patients, history of the disease at the population level (HIV Treatment prevalence, HIV Treatment incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: HIV Treatment patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for HIV Treatment market sizing, assessing market potential, and developing drug forecast models\nIdentify HIV Treatment patients segments through age groups, gender, and disease sub-types\nEvaluate HIV Treatment market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210514005178/en/\n'

Insignia and Partners Support CDC Demonstration Project for Uptake of Self-test Kits for HIV

Retrieved on: 
Monday, May 10, 2021
HIV/AIDS, Medical specialties, Pandemics, Infectious diseases, Health, HIV, HIV and pregnancy, HIV/AIDS denialism

The tests are the only oral fluid rapid over-the-counter HIV test approved in the U.S.

Key Points: 
  • The tests are the only oral fluid rapid over-the-counter HIV test approved in the U.S.
  • Nearly 40% of new HIV infections are transmitted by people who don\xe2\x80\x99t know they have HIV.
  • Important barriers to HIV testing include underestimation of risk, stress in waiting for test results, and difficulty finding time to test.
  • In addition to improving and maintaining the health of people with HIV, HIV testing is the bridge to treatment and prevention.\n\xe2\x80\x9cThe first step towards ending the HIV epidemic is to know your HIV status.

ViiV Healthcare receives positive CHMP opinion for long-acting regimen for the treatment of HIV

Retrieved on: 
Friday, October 16, 2020
Research, Infectious diseases, Clinical trials, Biotechnology, AIDS, Health, Pharmaceutical, Other Science, Science, Clinical medicine, Medicine, Prevention of HIV/AIDS, Health, Pre-exposure prophylaxis, RTT, HIV/AIDS, Hepatitis, Treatment as prevention, HIV and pregnancy, cabotegravir, rilpivirine and rilpivirine long-acting, ViiV Healthcare, GSK

Were proud to be providing different treatment options that meet the diverse needs of the HIV community.

Key Points: 
  • Were proud to be providing different treatment options that meet the diverse needs of the HIV community.
  • This treatment will offer people living with HIV an option with significantly less frequent dosing and comparable efficacy to daily oral regimens.
  • Cabotegravir is an INI developed by ViiV Healthcare for the treatment of HIV-1 in virologically suppressed adults.
  • Physicians should refer to current treatment guidelines for the management of HIV infection in patients co-infected with hepatitis B virus.

Global HIV Tests Market: Impact of COVID-19 for 2020 and Beyond - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 6, 2020
Professional services, Consulting, HIV/AIDS, Medical specialties, Hepatotoxins, Management of HIV/AIDS, Diagnosis of HIV/AIDS, Clinical medicine, Vaccines, Fellows of the Royal College of Physicians, HIV and pregnancy, HIV vaccine

The "HIV Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "HIV Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact)" report has been added to ResearchAndMarkets.com's offering.
  • The model discusses in detail the impact of COVID-19 on HIV Tests market for the year 2020 and beyond.
  • HIV tests are performed for two purposes: i) screening and diagnosis; or ii) monitoring of HIV-positive patients, particularly those undergoing antiretroviral therapy (ART).
  • Track device sales in the global and country-specific HIV Tests market from 2015-2030.

Express Scripts Leads Industry with New HIV Prevention Program

Retrieved on: 
Wednesday, March 4, 2020
Medicine, Clinical medicine, Retroviridae, Pre-exposure prophylaxis, Prevention of HIV/AIDS, HIV, HIV/AIDS, HIV and pregnancy

ST. LOUIS, March 4, 2020 /PRNewswire/ -- Express Scripts today announced a new program to bring simplicity, affordability, and predictability to HIV prevention through increased education and appropriate use of pre-exposure prophylaxis (PrEP) treatments.

Key Points: 
  • ST. LOUIS, March 4, 2020 /PRNewswire/ -- Express Scripts today announced a new program to bring simplicity, affordability, and predictability to HIV prevention through increased education and appropriate use of pre-exposure prophylaxis (PrEP) treatments.
  • The HIV Care ValueSM program is the industry's first value-based program to help prevent the transmission of HIV.
  • "Express Scripts can uniquely ensure employers and health plans will be part of achieving the goal of significantly reducing HIV transmission."
  • Increased Awareness: Express Scripts will engage with providers to offer additional resources to help them educate their patients on HIV prevention.

HIV Survey Finds Treatments Positively Impact Viral Suppression, Yet Stigma Impacts Quality of Life

Retrieved on: 
Monday, January 27, 2020
Prevention of HIV/AIDS, Viruses, Medical specialties, Hepatotoxins, Management of HIV/AIDS, Treatment as prevention, HIV, Health, HIV/AIDS, HIV and pregnancy

PHILADELPHIA, Jan. 27, 2020 /PRNewswire/ -- A new survey from Health Union, HIV In America 2019, finds that despite the positive impact of treatments that lead to viral suppression, people living with HIV continue to face various stigmas and stresses that negatively impact their lives.

Key Points: 
  • PHILADELPHIA, Jan. 27, 2020 /PRNewswire/ -- A new survey from Health Union, HIV In America 2019, finds that despite the positive impact of treatments that lead to viral suppression, people living with HIV continue to face various stigmas and stresses that negatively impact their lives.
  • Continued use of antiretroviral therapy is critical to achieving viral suppression and reducing a person's viral load to an undetectable level.
  • HIV In America 2019 respondents appear to represent a greater percentage of people who are virally suppressed compared to the national HIV population.
  • However, despite the impact of treatments for survey respondents, the findings indicated that various stresses remain.